Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

2020 has been a transformative year at Biosight, marked by meaningful clinical, regulatory and corporate progress, said Dr. Ruth Ben Yakar, Chief Executive Officer of Biosight.